Future applications of deoxycholic acid in body contouring

Jonathan M Sykes, Amir Allak, Brian Klink

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Deoxycholic acid (KybellaTM, Allergan Pharmaceuticals, Irvine, CA) is a novel injectable treatment used for the cosmetic reduction of redundant submental fat. By inducing adipose cell lysis, the soft tissue alteration induces subsequent contour change and sharpening of the cervicomental angle.The safety and efficacy have been well established in several prospective clinical trials and subsequent FDA approval for this purpose. This has provided an effective and less invasive alternative to surgical liposuction with virtually no recovery time and less overall discomfort. Given its success for use in this context, a logical step would be to extrapolate to other regions of the body where cosmetic deformity is caused by excessive adipose tissue. In the current article, the authors propose potential options for further use in various targeted areas where subcutaneous fat may be amenable to reduction with deoxycholic acid injection, understanding that such uses would be off-label and require an understanding of the regional anatomy and possible complications.

Original languageEnglish (US)
Pages (from-to)43-46
Number of pages4
JournalJournal of Drugs in Dermatology
Volume16
Issue number1
StatePublished - Jan 1 2017

Fingerprint

Deoxycholic Acid
Cosmetics
Regional Anatomy
Lipectomy
Body Regions
Injections
Subcutaneous Fat
Adipose Tissue
Fats
Clinical Trials
Safety
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

Future applications of deoxycholic acid in body contouring. / Sykes, Jonathan M; Allak, Amir; Klink, Brian.

In: Journal of Drugs in Dermatology, Vol. 16, No. 1, 01.01.2017, p. 43-46.

Research output: Contribution to journalArticle

Sykes, Jonathan M ; Allak, Amir ; Klink, Brian. / Future applications of deoxycholic acid in body contouring. In: Journal of Drugs in Dermatology. 2017 ; Vol. 16, No. 1. pp. 43-46.
@article{653a606bd87f4ada8dbf480095f33247,
title = "Future applications of deoxycholic acid in body contouring",
abstract = "Deoxycholic acid (KybellaTM, Allergan Pharmaceuticals, Irvine, CA) is a novel injectable treatment used for the cosmetic reduction of redundant submental fat. By inducing adipose cell lysis, the soft tissue alteration induces subsequent contour change and sharpening of the cervicomental angle.The safety and efficacy have been well established in several prospective clinical trials and subsequent FDA approval for this purpose. This has provided an effective and less invasive alternative to surgical liposuction with virtually no recovery time and less overall discomfort. Given its success for use in this context, a logical step would be to extrapolate to other regions of the body where cosmetic deformity is caused by excessive adipose tissue. In the current article, the authors propose potential options for further use in various targeted areas where subcutaneous fat may be amenable to reduction with deoxycholic acid injection, understanding that such uses would be off-label and require an understanding of the regional anatomy and possible complications.",
author = "Sykes, {Jonathan M} and Amir Allak and Brian Klink",
year = "2017",
month = "1",
day = "1",
language = "English (US)",
volume = "16",
pages = "43--46",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "1",

}

TY - JOUR

T1 - Future applications of deoxycholic acid in body contouring

AU - Sykes, Jonathan M

AU - Allak, Amir

AU - Klink, Brian

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Deoxycholic acid (KybellaTM, Allergan Pharmaceuticals, Irvine, CA) is a novel injectable treatment used for the cosmetic reduction of redundant submental fat. By inducing adipose cell lysis, the soft tissue alteration induces subsequent contour change and sharpening of the cervicomental angle.The safety and efficacy have been well established in several prospective clinical trials and subsequent FDA approval for this purpose. This has provided an effective and less invasive alternative to surgical liposuction with virtually no recovery time and less overall discomfort. Given its success for use in this context, a logical step would be to extrapolate to other regions of the body where cosmetic deformity is caused by excessive adipose tissue. In the current article, the authors propose potential options for further use in various targeted areas where subcutaneous fat may be amenable to reduction with deoxycholic acid injection, understanding that such uses would be off-label and require an understanding of the regional anatomy and possible complications.

AB - Deoxycholic acid (KybellaTM, Allergan Pharmaceuticals, Irvine, CA) is a novel injectable treatment used for the cosmetic reduction of redundant submental fat. By inducing adipose cell lysis, the soft tissue alteration induces subsequent contour change and sharpening of the cervicomental angle.The safety and efficacy have been well established in several prospective clinical trials and subsequent FDA approval for this purpose. This has provided an effective and less invasive alternative to surgical liposuction with virtually no recovery time and less overall discomfort. Given its success for use in this context, a logical step would be to extrapolate to other regions of the body where cosmetic deformity is caused by excessive adipose tissue. In the current article, the authors propose potential options for further use in various targeted areas where subcutaneous fat may be amenable to reduction with deoxycholic acid injection, understanding that such uses would be off-label and require an understanding of the regional anatomy and possible complications.

UR - http://www.scopus.com/inward/record.url?scp=85028516902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028516902&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 43

EP - 46

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 1

ER -